SOMERSET, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that CareCloud’s president and chief executive officer, A. Hadi Chaudhry, and chief financial officer, Bill Korn, will host investor meetings on Jan. 10-11, 2023, at the same time and location as the 41st Annual J. P. Morgan Healthcare Conference in San Francisco.
As previously announced, on Tuesday, Jan. 10, 2023, CareCloud will change its Nasdaq ticker symbol from MTBC to CCLD. CareCloud’s Series A Preferred Stock ticker will also change from MTBCP to CCLDP, and the Series B Preferred Stock ticker will change from MTBCO to CCLDO.
To arrange a meeting with CareCloud leadership, investors should contact CareCloud’s investor relations firm, ICR Westwicke, at This email address is being protected from spambots. You need JavaScript enabled to view it..
About CareCloud
CareCloud (Nasdaq: MTBC, MTBCP and MTBCO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. Approximately 40,000 providers count on CareCloud to help improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, telehealth and patient experience management (PXM) at www.carecloud.com.
For additional information, please visit our website at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
For additional information, please visit our website at www.carecloud.com. To view CareCloud’s latest investor presentations, read recent press releases, and listen to interviews with management, please visit ir.carecloud.com.
Company Contact:
Bill Korn
Chief Financial Officer
CareCloud, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.23 |
Daily Change: | 0.12 3.86 |
Daily Volume: | 282,559 |
Market Cap: | US$136.690M |
September 29, 2025 September 25, 2025 August 05, 2025 August 04, 2025 July 17, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load